방법 비교

	Prospective Phase IV Study	4상 연구
분야	역학	역학
계열	Process / pipeline	Process / pipeline
기원 연도	1970s–1980s (formalized in post-marketing regulatory frameworks)	Formalised 1970s–1990s (ICH E3 guideline 1994)
창시자	Regulatory and pharmaceutical research community (ICH E2E, EMA PASS guidelines)	Regulatory agencies and pharmaceutical industry (ICH, FDA, EMA frameworks)
유형	Observational / interventional post-marketing study design	Post-marketing observational or interventional study
원전	Strom, B.L. (Ed.). (2005). Pharmacoepidemiology (4th ed.). Wiley. ISBN: 978-0470863088	International Conference on Harmonisation (ICH). (1994). ICH Harmonised Tripartite Guideline: Structure and Content of Clinical Study Reports E3. ICH Secretariat.
별칭	prospective post-marketing surveillance study, prospective pharmacovigilance study, prospective post-authorization safety study, PASS (prospective)	post-marketing surveillance study, post-approval study, Phase 4 study, PMS study
관련	5	5
요약	A prospective Phase IV study is a post-marketing investigation conducted after a drug, device, or intervention has received regulatory approval, following participants forward in real time to collect safety, effectiveness, and utilization data under routine clinical practice conditions. Unlike retrospective designs that mine existing records, prospective enrollment allows pre-specified data collection, defined follow-up windows, and direct measurement of outcomes as they occur, making it central to post-authorization safety surveillance and long-term effectiveness research.	A Phase IV study is a post-marketing surveillance study conducted after a drug, device, or intervention has received regulatory approval. Its primary purpose is to monitor long-term safety, detect rare adverse events, assess effectiveness in routine clinical practice, and explore new indications or populations not adequately represented in earlier trials. Phase IV evidence accumulates continuously throughout a product's commercial life.